Biogen Idec Ma Inc.

Seikagaku Corporation

Biogen Idec, Inc.

Idec Pharmaceuticals Corporation

Takehiko Nakamura

Mitchell E Reff

William S Kloetzer

Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease conditions wherein inhibition of induced IgE production is therapeutically desirable, including allergic conditions, autoimmune diseases and inflammatory diseases.

Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics

Methods for inhibiting production of IgE in a human subject with an IgE-mediated allergic disorder by administering anti-CD23 antibodies.

&#x3b3;-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics

Anti-human CD23 monoclonal antibodies containing human gamma 1 constant domains and therapeutic uses are provided. These antibodies inhibit IL-4 induced IgE production by B-cells significantly greater than antibodies containing other constant domains.

Growing community of inventors

Higashiyamato, Japan

Takehiko Nakamura